Novartis

Novartis Seeks US Approval for Meningitis B Drug

Novartis Seeks US Approval for Meningitis B Drug

Seeking approval for its meningitis B vaccine Bexsero for adolescents and young people, Swiss drug-maker Novartis has submitted the vaccine to the U.S. Food and Drug Administration.

News: 
Location: 
Company: 

FDA Gives Early Approval to Novartis Drug for Lung Cancer

FDA Gives Early Approval to Novartis Drug for Lung Cancer

A new drug for the treatment of non-small cell lung cancer has sought the approval from the US Food and Drug Administration (FDA) on Tuesday.

Location: 
Company: 

NOVARTIS to Seek U.S. Approval for its Heart Drug, LCZ696

NOVARTIS to Seek U.S. Approval for its Heart Drug, LCZ696

The Switzerland based drug maker Novartis will seek approval of an experimental drug for chronic heart failure from regulators in major markets. Novartis AG said that its heart drug, LCZ696, has shown positive results before ending of its late-stage clinical trial.

The drug reported increased in survival rate of patients with heart diseases without being hospitalized in its clinical trial, termed as Paradigm-HF.

News: 
Location: 
Company: 

FDA Rejects Approval of Novartis drug Serelaxin for Heart Failure

FDA Rejects Approval of Novartis drug Serelaxin for Heart Failure

The U. S. Food and Drug Administration (FDA) panel have voted against the Novartis AG experimental heart failure drug, Serelaxin. The agency said that the company has given insufficient evidence in support of the proposed indication and moreover reviewers have also not released safety concerns about the drug.

Location: 
Laboratories: 
Company: 

Secukinumab, Novartis Psoriasis Drug Effective in Phase III Trial

Secukinumab, Novartis Psoriasis Drug Effective in Phase III Trial

Secukinumab, the experimental drug by the Novartis has proved successful in its two late-stage clinical trials to treat patients with moderate-to-severe plaque psoriasis. The findings of the Phase III studies were presented at the American Academy of Dermatology in Denver. The results revealed how the drug proved effective in clearing patients' skin when administered with a pre-filled syringe or autoinjector pen.

Location: 
Person: 
Company: 

Novartis Blood Cancer Drug Jakavi Shows Positive Results in Phase III Trial

Novartis Blood Cancer Drug Jakavi Shows Positive Results in Phase III Trial

Novartis AG has informed successful final stage trial of blood cancer drug Jakavi (ruxolitinib). The Swiss pharmaceutical major said that the rare blood cancer drug has shown improvement in two key measures of disease control. Jakavi maintained red blood cell volume among study subjects. The drug worked without the requirement for phlebotomy.

The drug has been found effective in incurable blood cancer, Polycythemia vera, which currently has very limited treatment options. The selective JAK 1 / 2 inhibitor has provided encouraging results in Phase III trials.

Company: 

Novartis AG acquires biotech firm CoStim Pharmaceuticals

Novartis AG acquires biotech firm CoStim

Novartis AG has announced acquisition of private biotechnology company CoStim Pharmaceuticals. The Swiss multinational pharmaceutical company plans to expand its cancer immunotherapy research with the latest acquisition.

Novartis is working closely with research team at University of Pennsylvania on CAR immunotherapy research project. CoStim acquisition will strengthen the position of Novartis in cancer immunotherapy.

Novartis has not disclosed the financial terms of the deal.

News: 
Company: 

Novartis Employees Possibly Breached Trial Protocol in Japan

Novartis Employees Possibly Breached Trial Protocol in Japan

Novartis Pharma K.K. (NPKK) acknowledged that employees of its Japanese subsidiary might have improperly handled data for a study of the cancer therapy, Tasigna. The Swiss drug maker claims that the employees had transferred data from research institutes to the University of Tokyo Hospitals for analysis, which is against the rules of the clinical trial.

In actual, the data was supposed to be transferred by research institutes directly to the hospital without being passed on by Novartis employees.

Location: 
Laboratories: 
Company: 

Novartis Sued in New York over Kick backs to Pharmacy

Novartis Sued in New York over Kick backs to Pharmacy

The New York Attorney General, Eric T. Scheniderman,told that the U.S. state has filed a suit against Novartis over charges that the Swiss drug maker granted bribes to a New York pharmacy company. The bribe was given in order to promote its Exjade drug to treat higher proportion of iron in the blood.

Location: 
Company: 

Popular Stories

Harley-Davidson to turn 8 Dyna motorbikes into new Softail bikes

Betting big on cruisers, the luxury motorcycle... Read More

Uber’s net loss declines as ride bookings grow

Uber Technologies reported lower loss by nearly 9... Read More

Samsung Galaxy Note 8 facing challenges on multiple fronts

The Samsung Galaxy Note 8 is facing an increasingly... Read More

Leaked reports reveal more about new BMW M5

Luxury carmaker BMW’s next-generation M5 car will... Read More